HOME >> BIOLOGY >> NEWS
UCSD discovery shows how embryonic stem cells perform 'quality control' inspections

Biologists at the University of California, San Diego have found a fundamental mechanism used by embryonic stem cells to assure that genetically damaged stem cells do not divide and pass along the damage to daughter stem cells.

Their discovery, detailed in an advance online publication of the journal Nature Cell Biology, solves the longstanding mystery of how embryonic stem cells, which have the potential to divide an unlimited number of times and differentiate to make all of the cell types in the body, are able to avoid duplicating cells that have sustained genetic damage.

"What we discovered is a primary mechanism that allows embryonic stem cells to perform quality control inspections during their self-renewal, the process by which these cells undergo unlimited cellular division to produce an unlimited number of daughter cells," says Yang Xu, an associate professor of biology at UCSD who headed the research team.

"Since DNA damage can occur during normal cellular propagation as well as after the exposure of cells to DNA-damaging radiation and chemicals, it is critical for the embryonic stem cells to develop stringent mechanisms to ensure the repair of DNA damage and prevent the passage of DNA damage to their daughter cells. Unrepaired DNA damage will cause genetic instability and, ultimately, cellular transformation into cancer cells."

Xu and his team made their discovery while working with embryonic stem cell lines from mice, which possess the same known properties and capabilities as human embryonic stem cells. They found that a protein, p53, known to play a critical role in the suppression of tumors in both humans and mice, is also used to maintain the genetic stability of embryonic stem cells.

The scientists, who included Tongxiang Lin, a UCSD postdoctoral fellow and the first author of the study, and Connie Chao, a graduate student in Xu's laboratory, discovered that p53 activated by DNA damage in mouse em
'"/>

Contact: Yang Xu
yangxu@ucsd.edu
858 822-1084
University of California - San Diego
26-Dec-2004


Page: 1 2

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. New proteomics research promises to revolutionize biomedical discovery
3. MU researchers make discovery in molecular mechanics of phototropism
4. International team to honor 30th anniversary of deep-sea vent discovery in Galpagos
5. Screening approach leads to discovery of gene linked to breast cancer
6. Lucky 13 as new gene discovery offers further hope for childhood blindness
7. Plants that produce more vitamin C may result from UCLA-Dartmouth discovery
8. Biting discovery: MU entomologist finds host of new aquatic insect species in Thailand
9. J&JPRD discovery may lead to new treatments for chronic sensitivity, pain caused by cold
10. Protein enables discovery of quantum effect in photosynthesis
11. Unicellular microRNA discovery

Post Your Comments:
(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
(Date:3/25/2015)... 26, 2015 Agnition announced today that ... American Farmer, airing for the first time at 7:30 ... American Farmer will explore the extremely important role soil ... with a patented Microbial Catalyst™ technology that enhances soil ... The segment will air again on April 28. , ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 Laboratory ... Top-Loading Balances and Analytical Balances to get best-performing ... line of weighing balances from the trusted brand ... Balances increase your efficiency by providing a ... of samples. Weighing modes include parts counting, percent ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
Cached News: